[ADVERT]
Share Name Share Symbol Market Type Share ISIN Share Description
Renalytix Plc LSE:RENX London Ordinary Share GB00BYWL4Y04 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -20.00 -2.86% 680.00 680.00 740.00 710.00 710.00 710.00 39,680 16:35:09
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -10.6 -16.0 - 491

Renalytix PLC Director/PDMR Shareholding

23/07/2021 11:30am

UK Regulatory (RNS & others)


Renalytix (LSE:RENX)
Historical Stock Chart


From Jun 2021 to Sep 2021

Click Here for more Renalytix Charts.

TIDMRENX

RNS Number : 3061G

Renalytix PLC

23 July 2021

Renalytix plc

("Renalytix" or the "Company")

Director/PDMR Dealing

New York, 23 July 2021 - Renalytix (LSE: RENX) announces that it has been advised of the sale by O. James Sterling, the Company's Chief Financial Officer, of 12,000 American Depositary Shares ("ADS"), each representing two ordinary shares of GBP0.0025 each in the capital of the Company ("Ordinary Shares"), under a Rule 10b5-1 trading plan established in accordance with Rule 10b5-1 under the U.S. Securities Exchange Act of 1934, as amended, and the EU Market Abuse Regulation as it forms part of UK law by virtue of the European Union (Withdrawal) Act 2018 ("MAR").

Rule 10b5-1 plans permit directors, officers and other company insiders to adopt, at times when they are not in possession of material, non-public information, or inside information, written plans for trading securities in a non-discretionary, pre-scheduled manner in the future.

Following completion of the sale, O. James Sterling is interested in 1,883,236 Ordinary Shares representing 2.60% of the current issued share capital of the Company.

For further information, please contact:

 
Renalytix plc                                                www.renalytix.com 
James McCullough, CEO                                          Via Walbrook PR 
 
Stifel (Nominated Adviser, Joint Broker)                    Tel: 020 7710 7600 
Alex Price / Nicholas Moore 
 
Investec Bank plc (Joint Broker)                            Tel: 020 7597 4000 
Gary Clarence / Daniel Adams 
 
Walbrook PR Limited             Tel: 020 7933 8780 or renalytix@walbrookpr.com 
Paul McManus / Lianne Cawthorne             Mob: 07980 541 893 / 07584 391 303 
 
 

About Kidney Disease

Kidney disease is now recognized as a public health epidemic affecting over 850 million people globally. The Centers for Disease Control and Prevention (CDC) estimates that 15% of US adults, or 37 million people, currently have chronic kidney disease (CKD). Further, the CDC reports that 9 out of 10 adults with CKD do not know they have it and 1 out of 2 people with very low kidney function who are not on dialysis do not know they have CKD*. Kidney disease is referred to as a "silent killer" because it often has no symptoms and can go undetected until a very advanced stage. Each year kidney disease kills more people than breast and prostate

cancer.    Every day, 13 patients in the United States die while waiting for a kidney transplant. 
   *    https://www.cdc.gov/kidneydisease/publications-resources/2019-national-facts.html 

About RenalytixAI

RenalytixAI is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. RenalytixAI's products are being designed to make significant improvements in kidney disease diagnosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery. For more information, visit www.renalytixai.com

The information contained in this notification is disclosed in accordance with the requirements of MAR.

 
 1    Details of the person discharging managerial responsibilities/person 
       closely associated 
 a)   Name                             O. James Sterling 
     -------------------------------  -------------------------------------------- 
 2    Reason for the notification 
     ----------------------------------------------------------------------------- 
 a)   Position/status                  Chief Financial Officer 
     -------------------------------  -------------------------------------------- 
 b)   Initial notification             Initial Notification 
       /Amendment 
     -------------------------------  -------------------------------------------- 
 3    Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     ----------------------------------------------------------------------------- 
 a)   Name                             Renalytix AI plc 
     -------------------------------  -------------------------------------------- 
 b)   Legal Entity Identifier          213800NTOH3FK3WER551 
     -------------------------------  -------------------------------------------- 
 4    Details of the transaction(s): section to be repeated for 
       (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions 
       have been conducted 
     ----------------------------------------------------------------------------- 
 a)   Description of                   ADS', each ADS representing two Ordinary 
       the financial instrument,        Shares of GBP0.0025 each. 
       type of instrument 
 
       Identification                   US75973T1016 
       code 
     -------------------------------  -------------------------------------------- 
 b)   Nature of the transaction        Sale of ADS' under a 10b5-1 trading plan 
     -------------------------------  -------------------------------------------- 
 c)   Currency                         US Dollar 
     -------------------------------  -------------------------------------------- 
 d)   Price(s) and volume(s)           Price(s)      Volume(s) 
     -------------------------------  ------------  ------------------------------ 
                                       $27.95        3,000 ADS (representing 
                                                      6,000 Ordinary Shares) 
 
                                        $28.00        3,000 ADS (representing 
                                                      6,000 Ordinary Shares) 
     -------------------------------  ------------  ------------------------------ 
 e)   Aggregated information 
       - Aggregated volume               6,000 ADS (representing 12,000 Ordinary 
       - Price                           Shares) 
       - Aggregated total                $27.975 
                                         $335,700 
     -------------------------------  -------------------------------------------- 
 f)   Date of the transaction          21 July 2021 
     -------------------------------  -------------------------------------------- 
 g)   Place of the transaction         Nasdaq Stock Exchange 
     -------------------------------  -------------------------------------------- 
 
 
 1    Details of the person discharging managerial responsibilities/person 
       closely associated 
 a)   Name                             O. James Sterling 
     -------------------------------  -------------------------------------------- 
 2    Reason for the notification 
     ----------------------------------------------------------------------------- 
 a)   Position/status                  Chief Financial Officer 
     -------------------------------  -------------------------------------------- 
 b)   Initial notification             Initial Notification 
       /Amendment 
     -------------------------------  -------------------------------------------- 
 3    Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     ----------------------------------------------------------------------------- 
 a)   Name                             Renalytix AI plc 
     -------------------------------  -------------------------------------------- 
 b)   Legal Entity Identifier          213800NTOH3FK3WER551 
     -------------------------------  -------------------------------------------- 
 4    Details of the transaction(s): section to be repeated for 
       (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions 
       have been conducted 
     ----------------------------------------------------------------------------- 
 a)   Description of                   ADS', each ADS representing two Ordinary 
       the financial instrument,        Shares of GBP0.0025 each. 
       type of instrument 
 
       Identification                   US75973T1016 
       code 
     -------------------------------  -------------------------------------------- 
 b)   Nature of the transaction        Sale of ADS' under a 10b5-1 trading plan 
     -------------------------------  -------------------------------------------- 
 c)   Currency                         US Dollar 
     -------------------------------  -------------------------------------------- 
 d)   Price(s) and volume(s)           Price(s)      Volume(s) 
     -------------------------------  ------------  ------------------------------ 
                                       $30.00        6,000 ADS (representing 
                                                      12,000 Ordinary Shares) 
     -------------------------------  ------------  ------------------------------ 
 e)   Aggregated information 
       - Aggregated volume               6,000 ADS (representing 12,000 Ordinary 
       - Price                           Shares) 
       - Aggregated total                $30.00 
                                         $180,000 
     -------------------------------  -------------------------------------------- 
 f)   Date of the transaction          22 July 2021 
     -------------------------------  -------------------------------------------- 
 g)   Place of the transaction         Nasdaq Stock Exchange 
     -------------------------------  -------------------------------------------- 
 
, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHEAEXDAASFEFA

(END) Dow Jones Newswires

July 23, 2021 06:30 ET (10:30 GMT)

1 Year Renalytix Chart

1 Year Renalytix Chart

1 Month Renalytix Chart

1 Month Renalytix Chart
ADVFN Advertorial
Your Recent History
LSE
RENX
Renalytix
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20210925 07:21:24